Pharmaceutical industry stakeholders have picked apart FDA’s draft guidance on circumstances that constitute delaying, denying, limiting or refusing a drug inspection, asking the agency to allow companies to prevent or limit certain products or parts of a facility from inspection without the fear of triggering a FDA Safety and Innovation Act provision that would deem the drug adulterated.
Section 707 of FDASIA adds section 501(k) to the Food, Drug, and Cosmetic Act, deeming adulterated a drug that “has...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?